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INTRODUCTION
Cell migration is the result of a complex balance between localized proteolysis, dynamic cell-extracellular matrix (ECM) interactions and cytoskeletal reorganization. The receptor for the urokinase-type plasminogen activator (uPAR) appears to be a key molecule in the coordination of these different events. uPAR, in fact, promotes cellassociated proteolysis by binding its specific ligand, the serine-protease urokinase (uPA), which converts locally the widely distributed zymogen plasminogen into active plasmin, a broad-spectrum protease which degrades ECM proteins either directly or by activating other proteases (1-2).
Furthermore, uPAR interacts with cell-adhesion specialized molecules, such as integrins of the beta1, beta2 and beta3 families (3) (4) (5) , thus regulating their functions, and binds vitronectin (VN), a component abundant in tumor-associated ECMs (6) . The interactions with integrins and VN are positively regulated by uPA (6) (7) . Both uPA and VN can induce uPARmediated cytoskeletal reorganization and cell-migration (8) (9) (10) (11) (12) .
uPAR is synthesized as a single polypeptide chain of 313 aminoacid residues, preceded by a 21 residues signal peptide. Post-translational events lead to the cleavage of the last 30 carboxyterminal residues and to the attachment of a glycophosphatydilinositol (GPI) tail to Gly 283 (13) . The mature protein has a three domain structure: D1 is the N-terminal domain, D2 connects D1 to D3, and D3 is the carboxyterminal domain which anchors the molecule to the cell membrane through the GPI tail (13) . However, in spite of the lack of a transducing cytoplasmic tail, the receptor is able to activate cell-signaling pathways, probably by interacting with other cellsurface molecules (14) .
uPA binds the D1 of the receptor, and retains its proteolytic activity after the binding; the activity can be inhibited by two specific inhibitors, type-1 (PAI-1) and type-2 (PAI-2) (1-2). PAI-1 also appears to be involved in the regulation of uPAR-mediated cell-migration, since it promotes the by guest on November 6, 2017 http://www.jbc.org/ Downloaded from internalization of the uPA-uPAR complex and competes with uPAR for the binding to VN (15) . The VN-binding domain of uPAR is controversial (6, 16) ; the intact uPAR molecule is however required for an efficient binding to both vitronectin (16, 17) and uPA (18) , thus suggesting the cooperation of different domains (19) . The region of uPAR involved in the interaction with integrins has not yet been identified. uPAR can be released by several cell lines and a soluble form of the receptor (suPAR) has been detected in human plasma and urine (20) (21) . The soluble form of the receptor, deprived of the D1 domain by cleavage with chymotripsin, is a potent chemoattractant for monocyte-like cells (22) . In fact, chymotripsin cleaves uPAR between Tyr 87-Ser 88, thus unmasking a region with chemotactic properties, corresponding to the 88-92 residues of uPAR (P88-92) (23) . It has been recently reported that P88-92-induced chemotaxis is mediated by the low-affinity receptor for the N-formyl-MetLeu-Phe (fMLP), a peptide of bacterial origin (24) .
Cell-surface uPAR also can be cleaved "in vitro", within the D1-D2 connecting region, by several proteolytic enzymes, such as chymotripsin, plasmin and uPA itself (25) (26) . Cleavage leads to the release of the D1 domain, thus leaving on the cell surface a two domains D2D3-uPAR. Cleaved forms of uPAR, lacking the uPA-binding domain, are widely expressed both "in vivo" and "in vitro", e.g. on the surface of different cell lines (25) (26) (27) (28) (29) , in normal and neoplastc thyroid tissues (26) , in blast cells of patients with acute leukemia (30) , in cystic fluids from benign and malignant ovarian tumors (31) , in human foreskin microvascular endothelial cells (32) and in human xenograft tumors implanted in mice (29, 33) . In monocyte-like cells, N-terminal sequencing of the cleaved forms and uPAR cleavage inhibition by uPA-inactivating antibodies, showed that uPA could be physiologically responsible for D1 removal, by cleaving the receptor at two specific sites, between Arg 83-Ala 84 and between Arg 89-Ser 90, in the D1-D2 linker region (34) . Thus, uPA-mediated cleavage can leave on the cell-surface a by guest on November 6, 2017 http://www.jbc.org/ Downloaded from truncated receptor exposing at the N-terminus an intact P88-92 (the sequence with chemotactic properties), or a truncated receptor where this specific sequence has been partially removed.
It has been recently reported that uPA could be involved in the cell-surface uPAR cleavage also "in vivo" (35) , and that the enzyme cleaves with high efficiency only the GPI-anchored receptor and not the soluble form (36) .
Since cleaved uPAR is unable to bind uPA and VN, uPA-mediated cleavage acts as a negative-feedback regulatory mechanism of the cell-surface associated plasminogen-activation and of cell adhesion to VN.
We now investigate whether the removal of D1 from the cell-surface uPAR can interfere also with other known functions of intact uPAR, such as cell adhesion, migration and proliferation. Moreover, we investigate if the presence, the exposure or the deletion of P88-92, whose unmasking appears to be necessary for the chemotactic activity of soluble uPAR, can play a role in the functions of the cell-anchored receptor. 
MATERIALS AND METHODS

Reagents
Co-immunoprecipitation
Immunoprecipitation was performed as previously described (3) . Cells (5x10 6 /sample) were washed twice with microtubule stabilization buffer (0.1 M Pipes, pH 6.9, 2 M glycerol, 1 mM EGTA, 1 mM magnesium acetate), and then extracted in 0.2% Triton X-100 additioned with protease inhibitors. The insoluble residue, enriched in cytoskeleton associated proteins, was solubilized in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% deoxycholate, 0.1% SDS, 1% Triton-X-100 and protease inhibitors), and preincubated with nonimmune serum and 10% protein A-Sepharose, for 2 h at 4°C. After centrifugation, supernatants were incubated with 2 µl of antisera to beta1, alfa3, alfa5, alfav integrins, with 2 µl of antiserum to caveolin, or with 2 µl of nonimmune serum, for 2 h at 4°C. After 30' incubation with 10% protein A-Sepharose at room temperature, immunoprecipitates were washed, subjected to 9% SDS-PAGE and analyzed by Western Blot, using R2 monoclonal anti-uPAR antibody, at a concentration of 1 µg/ml.
Western Blot
Cells were lysed in 1% Triton X-100/PBS in the presence of protease inhibitors (SIGMA); the protein content was measured by a colorimetric assay (BIORAD). 0,5-1 µg of protein of transfected cell lysates was electrophoresed on a 9% SDS-PAGE and transferred onto a PVDF membrane.
The membrane was blocked with 5% non-fat dry milk, and probed with 1 µg/ml of R2 or R4 anti-uPAR monoclonal antibodies directed to uPAR domains 2+3 and therefore able to detect both intact and truncated uPARs. 
Cell migration assay
Cell migration assays were performed in Boyden chambers, using 8 µm pore In a separate set of experiments, cells were pre-incubated for 1 h at room temperature with 5 µg/ml of 399 anti-uPAR policlonal antibody, or cultured for 18 h at 37° with 50 ng/ml Pertussis Toxin.
Reverse-Polymerase Chain Reaction
Total The resulting plasmid was subcloned in pcDNA3 and named D2D3wc-pcDNA3; it contained a cDNA coding the leader peptide connected to 95-313 residues of uPAR through the insertion of an additional L residue. Transfected cells were selected by Geneticin at 1.5 mg/ml; the resulting clones of each transfection were pooled and cultured in the presence of 0.5 mg/ml Geneticin.
RESULTS
Expression of uPAR-cDNAs in 293 cells
The cDNAs of two different truncated forms of uPAR were prepared. Both cDNAs coded for a uPAR devoid of D1 and formed by D2 and D3, but they (Fig.2, panel A) . The cDNAs of both uPAR truncated forms were expressed with a similar efficiency as compared to the expression of the intact uPAR cDNA. As expected, control V-293 cells did not express any form of uPAR (Fig.2, panel A) .
In order to investigate whether truncated uPARs were correctly delivered to the cell surface, transfected cell lysates were immunoprecipitated, after cellsurface biotinilation, with R4 anti-uPAR monoclonal antibody. Both uPAR truncated forms were labeled by biotin, such as the intact form, thus indicating their cell-surface expression (Fig.2, panel B) .
Cell-surface expression of uPARs was finally quantitated by flow cytometry with the 399 anti-uPAR polyclonal antibody; mean fluorescence intensity values of D2D3-293 and D2D3wc-293 cells varied of only +10.3% and -13.8%, respectively, as compared to uPAR-293 cells (Fig.2, panel C) .
In conclusion, these results showed that transfected cells expressed almost similar amounts of intact and truncated forms of uPAR on their surface and were therefore suitable for functional assays.
uPAR-integrin interaction
Intact uPAR is able to interact with different types of integrins and with caveolin, a protein associated with intracellular signaling pathways and cytoskeletal elements (3) (4) (5) . We tested the ability of uPARs truncated forms These results suggest that D1 removal, which abolishes uPAR-integrin interactions, negatively regulates also the integrin-mediated capability of intact uPAR to activate ERK and to increase cell proliferation.
uPAR and cell-migration
Soluble truncated uPAR, lacking D1 and containing an intact P88-92, is a potent chemoattractant for monocyte-like cells (23) , since it binds and activates the low affinity receptor for fMLP (FPRL1) (24) . We have therefore (Fig.8, upper panel) . fMLP-dependent uPAR-293 and D2D3-293 cell migration was inhibited by polyclonal anti-uPAR antibodies and by Pertussis Toxin (Fig. 8, lower panel) , thus indicating the involvement of both uPAR and FPR, which is a G-protein coupled receptor. uPAR-293 and D2D3-293 cell migration occurred at a fMLP concentration ranging between 10 nM and 1 µM, higher concentrations being not effective (data not shown); this observation confirms the involvement of the high-affinity rather than the low affinity receptor for fMLP, which requires 100 times higher fMLP concentration (39) . Its involvement in these process depends not only on its capability to bind extracellular proteins, such as urokinase and vitronectin, but also on its engagement in multiple lateral protein-protein interactions (14) . The intact three domain structure of the receptor is required for an efficient binding to extracellular uPA and VN (16) (17) (18) (19) . We now provide evidence that also the Since 293 cells express only the high affinity receptor for fMLP, we propose that uPAR D1-D2 linker region, directly or indirectly, interacts with this type of fMLP-receptor, thus contributing to its activation. Cell-surface uPAR expression could be required also for the activation of other different chemokine receptors, since it has been reported that it is necessary for human monocyte chemotaxis (38) and for adequate host defence against Pneumococcal Pneumonia, independently on its capability to interact with beta-2 integrins and uPA (44) .
Interestingly, a physical and functional interaction of the soluble form of uPAR (suPAR) with FPRL1 and not with FPR has been recently reported (24) .
Also the FPRL1 binding site of suPAR resides in the D1-D2 linker region and corresponds to residues 88-92, which must be unmasked by D1 removal in In conclusion, since uPAR is an ubiquitous receptor, it is probably required for physiological processes and its activity can be physiologically regulated by uPA-mediated cleavage. Up-regulation of uPA, which has been observed in several tumors, both in the stroma and in the tumor cells (13) , can increase uPAR expression (47) and stimulate its functions; cleavage, which has a limited efficiency (25) , may then become insufficient to regulate negatively the activity of uPAR, which can therefore contribute highly to proliferation, migration and tissue invasion of tumor cells.
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